Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.55 USD
Change Today +0.02 / 0.57%
Volume 4.4K
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

cleveland biolabs inc (CBLI) Snapshot

Open
$3.51
Previous Close
$3.53
Day High
$3.57
Day Low
$3.51
52 Week High
04/3/14 - $16.20
52 Week Low
02/11/15 - $3.07
Market Cap
12.2M
Average Volume 10 Days
56.0K
EPS TTM
$-2.93
Shares Outstanding
3.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLEVELAND BIOLABS INC (CBLI)

Related News

No related news articles were found.

cleveland biolabs inc (CBLI) Related Businessweek News

View More BusinessWeek News

cleveland biolabs inc (CBLI) Details

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with significant medical need. Its lead drug candidates include Entolimod, which is being developed as radiation countermeasure for prevention of death from acute radiation syndrome and as an oncology drug; and CBL0137, which is in two multi-center, single agent, dose escalation Phase I studies in subjects with advanced solid tumors. The company’s clinical stage product candidates comprise CBL0102, which has completed Phase I safety and tolerability study in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma; and Entolimod, which is in Phase I clinical trials for open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity in advanced cancer patients. Its preclinical stage product candidates include CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin. The company has license agreements and collaborations with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, and Buffalo BioLabs. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

13 Employees
Last Reported Date: 02/27/15
Founded in 2003

cleveland biolabs inc (CBLI) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $302.3K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $119.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $283.2K
Compensation as of Fiscal Year 2014.

cleveland biolabs inc (CBLI) Key Developments

Cleveland BioLabs, Inc. Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation

Cleveland BioLabs, Inc. announced that a maximally tolerated dose has been reached and that dosing has been completed in a Phase 1 healthy subject study of CBLB612, an investigational drug in development for mobilization of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression. The objectives of the study include establishing a maximally tolerated dose, evaluating the safety profile and pharmacokinetics of CBLB612, and characterizing the type, quantity and timing of HSC mobilization. Analysis of data from the 56 healthy volunteers enrolled in the study is ongoing and data are expected to be reported in the second quarter of 2015. This study is partially funded through a contract from the Ministry of Industry and Trade of the Russian Federation.

Cleveland BioLabs, Inc. Receives Non-Compliance Notice From NASDAQ

On March 10, 2015, Cleveland BioLabs, Inc. received a deficiency letter from The NASDAQ Stock Market LLC indicating that, as of December 31, 2014 the company’s reported stockholders’ equity of $1,786,102 did not meet the $2,500,000 minimum required to maintain continued listing, as set forth in NASDAQ Listing Rule 5550(b)(1), and that as of March 9, 2015 the company does not meet the alternatives of market value of listed securities or net income from continuing operations. The notification has no immediate effect on the listing of the company’s common stock on the Nasdaq Capital Market. Under NASDAQ rules, the company has 45 calendar days to submit a plan to regain compliance. If the company’s plan is accepted, NASDAQ can grant an extension of up to 180 calendar days, or until September 7, 2015, to evidence compliance. If the company fails to regain compliance, the company’s stock will be subject to delisting by NASDAQ. The company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements.

Cleveland BioLabs, Inc. Auditor Raises 'Going Concern' Doubt

Cleveland BioLabs, Inc. filed its 10-K on Feb 27, 2015 for the period ending Dec 31, 2014. In this report its auditor, Meaden & Moore, Ltd., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBLI:US $3.55 USD +0.02

CBLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBLI.
View Industry Companies
 

Industry Analysis

CBLI

Industry Average

Valuation CBLI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLEVELAND BIOLABS INC, please visit www.cbiolabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.